The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

Disclosed is a system, a kit, a use and an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The system and method are based on the insight to apply a clustering technique to a reference set of patient data, and then further discriminating the sets of bio markers to be applied. The clusters are determined on the basis of the biomarkers Hepatocyte Growth Factor (HGF), Matrix metalloproteinase 8 (MMP8), and Matrix metalloproteinase 9 (MMP9). The actual classification of the patient is done on the basis of the measurement of the concentrations of either of two sets of biomarkers. For one cluster these are Interleukin-1? (IL1?), Interleukin-6 (IL6), and Collagen Telopeptide. For the other cluster, these are HGF and metallopeptidase inhibitor 1 (TIMP1).

The present disclosure provides methods for the detection of multiple analytes using a single solid phase. The present disclosure also relates to the preparation of solid phases that include receptacles having affixed thereto antibodies directed to at least two different analytes. The methods of the present disclosure can be used, for example, for the quantitative detection of analytes in a sample and the measurement thereof.

We describe a method of detecting pre-eclampsia in a cell, tissue, organ or organism, the method comprising detecting a modulated level of expression, activity or amount of a pre-eclampsia biomarker polypeptide selected from the group consisting of PlGF, FLT1, BNP, ANP, CD9, PAI-1, TGF , PCT, SI 00b, TIMP1, CD 105 and IL6 in or of a microparticle type (selected from a CTB binding microparticle and an Annexin V binding microparticle) from the cell, tissue, organ or organism, as compared to level of expression, activity or amount of the pre-eclampsia biomarker polypeptide in the same microparticle type in a cell, tissue, organ or organism not sufferin from pre-eclampsia.

The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.

The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Disclosed are antibody arrays for the detection of cancer in a human or animal subject, comprising a solid support having disposed thereon in a predetermined spatial configuration, a panel of antibodies specific to biomarkers comprising CA-125, MSP-, TIMP-4, PDGF-R and OPG, wherein the panel comprises a first antibody or fragment thereof that specifically binds CA-125, a second antibody or fragment thereof that specifically binds MSP-, a third antibody or fragment thereof that specifically binds TIMP-4, a fourth antibody or fragment thereof that specifically binds PDGF-R, and a fifth antibody or fragment thereof that specifically binds OPG. Also disclosed are systems containing the arrays and methods of using the arrays to detect cancer such as ovarian cancer.

The present invention relates to a method for diagnosing whether a subject may be at risk for or may suffer from cancer wherein (significantly) lower or (significantly) higher binding of a binding agent to a particular glycan structure of a biomarker glycoprotein compared to a control sample is indicative for said subject to be at risk for or to suffer from cancer. The present invention further relates to a kit for performing said for method of diagnosing whether a subject may be at risk for or may suffer from cancer, comprising a binding agent capable to bind to a glycan structure of a biomarker protein.

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.